We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment With Enfuvirtide (Fuzeon) Associated With Two Active Molecules (AMPHORE)

This study has been terminated.
(difficult to include patients)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00937729
First Posted: July 13, 2009
Last Update Posted: February 16, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Hoffmann-La Roche
Information provided by (Responsible Party):
University Hospital, Rouen
July 10, 2009
July 13, 2009
February 16, 2012
June 2009
January 2011   (Final data collection date for primary outcome measure)
viral load compliance [ Time Frame: one year ]
Same as current
Complete list of historical versions of study NCT00937729 on ClinicalTrials.gov Archive Site
statistical analysis of MOS HIV [ Time Frame: one year ]
Same as current
Not Provided
Not Provided
 
Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment With Enfuvirtide (Fuzeon) Associated With Two Active Molecules
Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment Containing Enfuvirtide (Fuzeon) Associated With Two Active Molecules
In case of lack of compliance in HIV1 patients, the investigators hope to prove that enfuvirtide injection during almost 3 months, with nurse help at home and therapeutic education may contribute to obtain a good compliance more than 95% in these patients.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
All patients HIV1 infected in virological failure (viral load > 50 copies/ml) by lack of compliance,old of more than 18 years, who never received enfuvirted and without opportunistic infection, yet treated by almost one molecule of each group.
  • HIV1 Infection
  • HIV Infections
Not Provided
enfuvirtide
all patients would received enfuvirtide and and optimised background
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
4
December 2011
January 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • virological failure, more than 18 years, prouved lack of compliance, with no sub-optimal treatment, in ambulatory status.

Exclusion Criteria:

  • hospitalization,HIV2 infection,pregnancy,preliminary treatment with enfuvirtide,chimiotherapy , opportunistic infection in progress
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT00937729
2008/122/HP
Yes
Not Provided
Not Provided
University Hospital, Rouen
University Hospital, Rouen
Hoffmann-La Roche
Principal Investigator: BORSA-LEBAS Françoise CHU Hôpitaux de Rouen
University Hospital, Rouen
February 2012